Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters

Journal of Biopharmaceutical Statistics

Volumn 18, Issue 6, 2008, Pages 1084-1102

  Bertrand, Julie ^a   Comets, Emmanuelle ^a   Mentre, France ^a  

^a INSERM   (France)

Author keywords

Genetics; Model selection; Nonlinear mixed effects model; NONMEM; Pharmacokinetics; Test

Indexed keywords

INDINAVIR; RITONAVIR;

ADULT; ALGORITHM; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

ADULT; ALGORITHMS; ANALYSIS OF VARIANCE; BAYES THEOREM; COMPUTER SIMULATION; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LIKELIHOOD FUNCTIONS; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NONLINEAR DYNAMICS; P-GLYCOPROTEIN; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; SOFTWARE;

EID: 57349187668     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400802369012     Document Type: Article

References (41)

1. Akaike, H. (1974). A new look at the statistical model identification. IEEE Trans. Automat. Contr. 19:716-723.
2. Beal, S. L. (2005). Conditioning on certain random events associated with statistical variability in PK/PD. J. Pharmacokinet. Pharmacodyn. 32:213-243.
3. Benjamini, Y., Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B Met. 57:289-300.
4. Bodor, M., Kelly, E. J., Ho, R. J. (2005). Characterization of the human MDR1 gene. AAPS J. 7:E1-E5.
5. Bozdogan, H. (1987). Model selection and Akaike's information criteria (AIC): The general theory and its analytical extensions. Psychometrika 52:345-370.
6. Brendel, K., Legrand, M., Taburet, A. M., Baron, G., Goujard, C., Mentre, F. (2005). Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. Fundam. Clin. Pharmacol. 19:373-383.
7. Burnham, K. P., Anderson, D. R. (2002). Model Selection and Multimodel. A Practical Information - Theoric Approach. New York: Springer-Verlag.
8. Comets, E., Mentré, F. (2001). Evaluation of tests based on individual vs population modelling to compare dissolution curves. J. Biopharm. Stat. 11:107-123.
9. Comets, E., Verstuyft, C., Lavielle, M., Jaillon, P., Becquemont, L., Mentré, F. (2007). Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur. J. Pharmacol. 63:437-449.
10. Csajka, C., Marzolini, C., Fattinger, K., Decosterd, L. A., Telenti, A., Biollaz, J., Buclin, T. (2004). Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 48:3226-3232.
11. Fellay, J., Marzolini, C., Meaden, E., Back, D., Buclin, T., Chave, J. (2002). Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter gene MDR1: A pharmacogenetic study. Lancet 359:30-36.
12. Gabrielsson, J., Weiner, D. (1999). Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm: Apotekarsocieteten.
13. Girard, P., Mentré, F. (2005). A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. PAGE 14:Abstr 834.
14. Goujard, C., Legrand, M., Panhard, X., Diquet, B., Duval, X., Peytavin, G., Vincent, I., Katlama, C., Leport, C., Bonnet, B., Salmon-Ceron, D., Mentre, F., Taburet, A. M. (2005). High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. Clin. Pharmacokinet. 44:1267-1278.
15. Henningsson, A., Marsh, S., Loos, W. J., Karlsson, M. O., Garsa, A., Mross, K., Mielke, S., Vigano, L., Locatelli, A., Verweij, J., Sparreboom, A., McLeod, H. L. (2005). Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. 11:8097-8104.
16. Innocentia, F., Liua, W., Chenb, P., Desaia, A. A., Dasb, S., Rataina, M. J. (2005). Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes. Pharmacogenet. Genomics 15:295-301.
17. Inomata, S., Nagashima, A., Itagaki, F., Homma, M., Nishimura, M., Osaka, Y., Okuyama, K., Tanaka, E., Nakamura, T., Kohda, Y., Naito, S., Miyabe, M., Toyooka, H. (2005). CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin. Pharmacol. Ther. 78:647-655.
18. Kappelhoff, B. S., Huitema, A. D., Sankatsing, S. U., Meenhorst, P. L., Van Gorp, E. C., Mulder, J. W., Prins, J. M., Beijnen, J. H. (2005). Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br. J. Clin. Pharmacol. 60:276-286.
19. Kerbusch, T., Wählby, U., Milligan, P., Karlsson, M. (2003). Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first pass metabolism, CYP2D6 genotype and formulation-dependant bio availability. Br. J. Clin. Pharmacol. 56:639-652.
20. Licinio, J., Wong, M. L. (2002). Pharmacogenomics: The Search for Individualized Therapy. Weinheim: Wiley-VCH.
21. Machin, D., Campbell, M., Fayers, P., Pinol, A. (1997). Sample Size Tables for Clinical Studies. Oxford: Blackwell Science.
22. Mamiya, K., Hadama, A., Yukawa, E., Ieiri, I., Otsubo, K., Ninomiya, H., Tashiro, N., Higuchi, S. (2000). CYP2C9 polymorphism effect on phenobarbiton kinetics in Japanese patients with epilepsy: Analysis by population phamacokinetics. Eur. J. Clin. Pharmacol. 55:821-825.
23. Marzolini, C., Paus, E., Buclin, T., Kim, R. B. (2003). Polymorphisms in Human MDR1 (Pglycoprotein): Recent advances and clinical relevance. Clin. Pharmacol. Ther. 75:13-33.
24. Meerum, T. J., Malingre, M., Beijnen, J., Ten, B., Huinink, W., Rosing, H., Koopman, F., et al. (1999). Co-administration of cyclosporine A enables oral therapy with paclitaxel. Clin. Cancer Res. 5:3379-3384.
25. Mentré, F., Duval, X., Rey, E., Peytavin, G., Auleley, S., Legrand, M., Biour, M., Bouxin, A., Goujard, C., Taburet, A., Katlama, C., Diquet, B., Lascoux, C., Tréluyer, J. M., Salmon-Céron, D. (2005). Prospective Trial to Evaluate How Therapeutic Drug Monitoring of Protease Inhibitors Increases Virologic Success and Tolerance of HAART (COPHAR 2-ANRS 111 Trial). 12th Conference on Retroviruses and Opportunistic Infections. Boston.
26. Min, D. I., Ellingrod, V. L., Marsh, S., McLeod, H. (2004). CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. 26:524-528.
27. Panhard, X., Mentré, F. (2005). Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials. Stat. Med. 24:1509-1524.
28. R Development Core Team (2006). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
29. Raftery, A. E. (1995). Bayesian model selection in social research (with discussion). Sociol. Methodol. 111-195.
30. Retout, S., Comets, E., Samson, A., Mentre, F. (2007). Design in nonlinear mixed effects models: Optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. Stat. Med. 26:5162-5179.
31. Retout, S., Mentre, F. (2003). Optimization of individual and population designs using Splus. J. Pharmacokinet. Pharmacodyn. 30:417-443.
32. Roe, D. J. (1997). Comparison of population pharmacokinetic modeling methods using simulated data: results from the Population Modeling Workgroup. Stat. Med. 16:1241-1257; discussion 1257-1262.
33. Sakaeda, T., Nakamura, T., Okumura, K. (2002). MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25:1391-1400.
34. Samson, A., Lavielle, M., Mentré, F. (2007). The SAEM algorithm for group comparison test in longitudinal data analysis based in nonlinear mixed-effects model. Stat. Med. 26:4860-4875.
35. Schwartz, G. (1978). Estimating the dimension of a model. Ann. Stat. 6:461-464. Sheiner, L., Beal, S. (1998). NONMEM Version 5.1. San Francisco: University of California, NONMEM Project Group.
36. Sugiura, N. (1978). Further analysis of the data by Akaike's information criterion and the finite corrections. Communication in Statistics. Theory and Methods 7:13-26.
37. Taguchi, M., Fujiki, A., Iwamoto, J., Inoue, H., Tahara, K., Saigusa, K., Horiuchi, I., Oshima, Y., Hashimoto, Y. (2006). Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in japanese patients with arrhythmias. Biol. Pharm. Bull. 29:517-521.
38. Verstuyft, C., Marcellin, R., Morand-Joubert, L., Launay, O., Brendel, K., Mentré, F., Peytavin, G., Gérard, L., Becquemont, L., Aboulker, J. P. (2005). Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to HAART. AIDS 19:2127-2131.
39. Wählby, U., Jonsson, E. N., Karlsson, M. O. (2001). Assessment of actual significance levels for covariate effects in NONMEM. J. Pharmacokinet. Pharmacodyn. 28:231-252.
40. Wang, Y. (2007). Derivation of various NONMEM estimation methods. J. Pharmacokinet. Pharmacodyn. 34:575-593.
41. Yamaguchi, H., Hishinuma, T., Endo, N., Tsukamoto, H., Kishikawa, Y., Sato, M., Murai, Y., Hiratsuka, M., Ito, K., Okamura, C., Yaegashi, N., Suzuki, N., Tomioka, Y., Goto, J. (2006). Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int. J. Gynecol. Cancer 16:979-985.